X hits on this document

440 views

0 shares

0 downloads

0 comments

31 / 170

13

OVERVIEW OF DEVELOPMENT PROGRAM

14

ROBERT WOLF, M.D., F.A.C.C.

7

Medicine and Biostatistics and Epidemiology at the University of Pennsylvania School of

8

Medicine.

18

not most, patients fail to achieve the ADA recommended target of A1c less than 7.0%.

19

As shown in this slide, data from recent surveys indicate the majority of

20

patients with type 2 diabetes in the US, the UK, and in Europe have A1c values above

4

Chief of the Division of Infectious Diseases at Georgetown University School of

5

Medicine.

10

you may have within their respective areas of expertise. I would now like to ask Dr.

11

Wolf to come forward and to present an overview of our development program. Dr.

12

Wolf.

16

a perspective on why it is important to develop novel therapies for type 2 diabetes.

17

Although several agents are available to treat the hyperglycemia type 2 diabetes, many, if

21

7.0. Some of the currently available agents have tolerability or safety concerns including

22

GI intolerability, risk for hypoglycemia, weight gain, and concerns regarding

23

cardiovascular safety.

6

Dr. Brian Strom, who is Professor of Public Health and Preventive

30

9

These individuals will also be available to address specific questions that

15

Good morning. Prior to describing our development program, I’ll provide

Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com

1

Dr. Mark Gorrell, who is Associate Professor at the Centenary Institute

2

3

of Cancer Medicine in Cell Biology at the University of Sydney.

Dr. Princy Kumar, who is Professor Of Medicine and Microbiology and

Document info
Document views440
Page views440
Page last viewedSun Dec 04 16:48:03 UTC 2016
Pages170
Paragraphs7975
Words54271

Comments